Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided? A pilot study
- 23 July 2018
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 37 (2) , 253-259
Abstract
In patients considered for active surveillance (AS), the use of MRI and targeted biopsies (TB) at entry challenges the approach of routine “per protocol” repeat systematic biopsies (SB) at 1 year. This pilot study aimed to assess whether an approach of performing repeat biopsies only if PSA kinetics are abnormal would be safe and sufficient to detect progression.Keywords
This publication has 20 references indexed in Scilit:
- Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the LiteratureEuropean Urology, 2015
- Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate CancerJournal of Urology, 2014
- Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS StudyEuropean Urology, 2013
- Magnetic Resonance Imaging for Predicting Prostate Biopsy Findings in Patients Considered for Active Surveillance of Clinically Low Risk Prostate CancerJournal of Urology, 2012
- Comprehensive analysis of post‐diagnostic prostate‐specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patientsBJU International, 2012
- Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed ExpectantlyEuropean Urology, 2009
- Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experienceBJU International, 2007
- Predictors of Histological Disease Progression in Untreated, Localized Prostate CancerJournal of Urology, 2007
- PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden sectionInternational Journal of Cancer, 2006
- Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancerCancer, 1993